There is a growing imperative for cardiology care models and clinical trials to better reflect the realities of aging.
At the

There is a growing imperative for cardiology care models and clinical trials to better reflect the realities of aging.
At the

Amazon.com recently announced strong third-quarter 2025 results, highlighted by a surge in AWS revenue and the signing of a landmark multi-year, US$38 billion cloud services agreement with OpenAI to support advanced AI workloads.
This collaboration marks OpenAI’s first major cloud partnership outside of Microsoft, underscoring Amazon’s strengthening position in artificial intelligence infrastructure and cloud computing.
We’ll explore how the new OpenAI partnership and AWS growth momentum could reshape Amazon’s investment narrative around cloud and AI innovation.
Uncover the next big thing with financially sound penny stocks that balance risk and reward.
To own Amazon.com shares, you have to believe the company can translate its scale in e-commerce and technology into leadership in cloud and AI, offsetting regulatory and cost pressures. The landmark US$38 billion multi-year cloud partnership with OpenAI and recent surge in AWS revenue offer a clear short-term growth catalyst, but the demands of rapid innovation and rising capital intensity remain the primary risk to margins and overall earnings. The announcement helps the catalyst, but does not materially erase the risk.
Among announcements, the expanded collaboration between AWS and Verizon to provide resilient, high-capacity infrastructure for AI workloads stands out. This builds on AWS’s momentum by supporting large-scale deployments for clients pursuing advanced AI applications, reinforcing the thesis that Amazon is making meaningful progress capturing the next wave of cloud and AI adoption.
However, increased capital needs and supply constraints tied to supporting these ambitious partnerships are risks investors must not ignore…
Read the full narrative on Amazon.com (it’s free!)
Amazon.com’s outlook suggests revenues of $905.9 billion and earnings of $111.9 billion by 2028. This is based on an assumed annual revenue growth rate of 10.6% and represents an increase in earnings of $41.3 billion from the current $70.6 billion.
Uncover how Amazon.com’s forecasts yield a $287.57 fair value, a 18% upside to its current price.
142 fair value estimates from the Simply Wall St Community place Amazon.com’s worth between US$173.76 and US$294.90 per share. With AWS’s growing capital demands and heightened competition, your outlook on future margin resilience may tip your own view on the company’s true value.
Explore 142 other fair value estimates on Amazon.com – why the stock might be worth 29% less than the current price!

Famous Pakistani comedian and television host Ayaz Samoo has made a surprising revelation, stating that male actors in the entertainment industry also undergo lip botox and other facial beauty procedures to enhance their appearance.
Speaking on a…

In the deep waters off central Japan, scientists have discovered a pale pink sea anemone, named Paracalliactis tsukisome, that builds its own shell-like home – then shares it with a hermit crab partner.
The newly described species forms an…

Lavrov said Putin’s November 5 order on a possible nuclear test is being implemented and reviewed
Putin order was in response to President Donald Trump’s surprise announcement last week that the US would resume testing, says Russian FM. PHOTO:…

Over 26 weeks, the complement C5 inhibitor gefurulimab showed its ability to produce statistically significant improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score, a clinically meaningful result, as well as reduce Quantitative Myasthenia Gravis (QMG) total scores at week 4 and week 26.1 These new top-line results from the phase 3, randomized, double-blind, placebo-controlled PREVAIL study (
Compared with conventional monoclonal antibodies, which typically require intravenous infusion by a health care professional, gefurulimab has the added convenience of being available as a prefilled syringe or autoinjector, Gwathmey explained. Gefurulimab is administered subcutaneously, with its low molecular weight and ability to extend the half-life of albumin—its dual-binding activity blocks C5 activation and binds to the liver-produced protein—key to its weekly administration.2
The adult patients evaluated in PREVAIL had anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalized
Overall, most patients had MGFA class II disease (36.6% and 34.9%) or class III disease (58.0% and 59.7%), mean (SD) MG duration of 9.2 (8.45) and 8.2 (8.79) years, mean MG-ADL score of 9.0 years (across both groups), and mean QMG score of 14.9 (4.38) or 14.7 (4.39). The least squares mean (LSM) change in MG-ADL was –4.2 (0.29) from gefurulimab and –2.6 (0.27) from placebo, for a treatment difference of –1.6 (0.40) (95% CI, –2.4 to –0.8; P < .0001). The early MG-ADL score improvement seen in week 1 after the loading dose was sustained through week 26.
For QMG change, the treatment difference seen by week 4 (LSM, –1.8 [0.37]; 95% CI, –2.5 to –1.1; P < .0001) rose through week 26 (LSM, –2.1 [0.50]; 95% CI, –3.1 to –1.1; P < .0001). As with the treatment cohort, the improvement first seen at week 4 was sustained through week 26.
“People living with gMG face fluctuating and often debilitating symptoms, including loss of muscle function and severe weakness, Gwathmey said
Treatment-emergent adverse events were typically injection site reactions (9.9%), headache (9.9%), and back pain (7.6%) among the gefurulimab group and headache (12.4%), diarrhea (8.5%), and upper respiratory tract infection (7.8%) among the placebo group. There were more TEAEs in the gefurulimab vs the placebo group (75.6% vs 80.6%), but these rates were considered similar overall.
Of the patients from the original PREVAIL treatment group, 4 discontinued treatment during the study, and all remaining 127 patients entered the open-label extension (OLE) analysis, which is investigating gefurulimab over a maximum of 202 weeks. Of the placebo group, 7 discontinued treatment and all remaining 122 patients entered the OLE analysis.
“Based on these clinical benefits and the advantage of self-administered [subcutaneous] weekly dosing,” the study authors concluded,” gefurulimab may offer patients with AChR-Ab+ gMG a convenient and effective treatment option.”
References

NASA announced a scientific high point as more than 5,000 planets are confirmed to exist beyond the solar system.
“65 new worlds push the number of exoplanets confirmed by @NASA above 5,000,” the agency wrote Monday on Twitter. “This…

A body that weighs as much as a small airplane should face steep odds against cancer. You may expect that from a creature packed with billions of cells, each with a chance to slip into danger as years pass.
Yet the bowhead whale, which can live…

Administering PD-1 inhibitor ezabenlimab with modified docetaxel, cisplatin, and fluorouracil (mDCF) reached the primary end point of clinical complete response (CR) among patients with stage III squamous cell anal carcinoma (SCAC), according to findings from the phase 2 INTERACT-ION trial (NCT04719988) published in The Lancet Oncology.1
Among those who were evaluable for the first radiological assessment following induction therapy, data showed an objective response rate (ORR) of 93% (n = 49/53), which included clinical CRs in 25% (n = 13/53) and partial responses (PRs) in 68% (n = 36/53). Subsequently, 75% (n = 38/51) proceeded to receive involved-node chemoradiotherapy (INRT), and 26% (n = 13/53) received standard concurrent chemoradiotherapy (CRT).
At 40 weeks across the modified intent-to-treat (ITT) population, 77.8% (95% CI, 66.5%-86.7%) achieved a clinical CR, with corresponding rates of 86.8% among those who received INRT and 69.2% in those who received concurrent CRT. With a median follow-up of 23.0 months (95% CI, 16.5-29.1), data showed that the median progression-free survival (PFS), disease-free survival (DFS), and overall survival (OS) were not estimable. Post hoc analysis findings showed 12-month and 24-month rates, respectively, of 85.2% (95% CI, 76.2%-95.2%) and 81.4% (95% CI, 71.7%-92.5%) for PFS, 86.1% (95% CI, 77.1%-96.2%) and 80.0% (95% CI, 66.6%-96.0%) for DFS, and 94.4% (95% CI, 88.5%-100.0%) and 84.3% (95% CI, 73.6%-96.5%) for OS.
“[T]his phase 2 study met its primary endpoint, showing antitumor activity (clinical [CR] rates) and a manageable safety profile for ezabenlimab and mDCF induction when given with INRT in patients with locally advanced SCAC,” lead study author Stefano Kim, MD, from the Department of Medical Oncology at Centre Hospitalier Universitaire de Besançon in Besançon, France, wrote with coauthors in the publication.1 “These promising activity outcomes support further investigation, and ongoing ancillary immunomonitoring analyses might provide insights into immune modulation and help to better understand the potential synergistic effect of this combination strategy.”
In the open-label, single-arm, phase 2 trial, 54 patients received at least 1 cycle of treatment in the modified ITT population. Patients were assigned to receive induction therapy with docetaxel at 40 mg/m2 on day 1, cisplatin at 40 mg/m2 on day 1, and fluorouracil at 1200 mg/m2 on days 1 and 2 plus ezabenlimab at 240 mg intravenously every 3 weeks for 3 cycles. Those who did not experience a response and had progressive disease per RECIST v1.1 criteria received standard concurrent CRT; those without progressive disease continued with 2 additional cycles of mDCF and 1 additional cycle of ezabenlimab. Those with a major response and pathological CR or near-CR following these additional cycles then received INRT plus ezabenlimab maintenance at 240 mg every 3 weeks for 7 cycles; patients without a major response underwent standard concurrent CRT.
The trial’s primary end point was the clinical CR rate at 40 weeks. Secondary end points included pathological CR or near-CR rate, biological CR rate, ORR, OS, PFS, DFS, and safety.
Patients 18 years and older with histologically confirmed SCAC, locally advanced disease, and an ECOG or WHO performance status of 0 or 1 were eligible for enrollment on the trial.2 Having adequate hematologic and end-organ function was another requirement for study entry.
The median age was 64.0 years in the modified ITT population, and most patients were female (76%). Additionally, most of this group had an ECOG performance status of 0 (56%), positive HPV circulating tumor DNA status (74%), stage T3 disease (44%), and stage N1a (33%) or N1c disease (33%).
Three patients discontinued induction therapy following investigator’s decision (n = 1); grade 3 febrile neutropenia, grade 3 typhlitis, and sepsis (n = 1); and progressive disease (n = 1). Additionally, 5 discontinued maintenance therapy due to disease progression (n = 1) or treatment-limiting toxicities (n = 4).
At least 1 adverse effect (AE) occurred in 100% of patients who received induction therapy, 97% for INRT, 100% for standard concurrent CRT, and 80% for ezabenlimab maintenance. Across these treatment phases, 17% to 92% experienced at least 1 grade 3 or higher AE, 63% to 100% experienced a treatment-related AE, and 14% to 92% had a grade 3 or higher TRAE.
Grade 3 TRAEs during ezabenlimab maintenance included increased lipase (3%), cytomegalovirus colitis (3%), and lichen planus (3%). Data showed no treatment-related deaths. Investigators noted no safety signals exceeding the Pocock-type boundary for dose-limiting toxicities when monitoring the safety of ezabenlimab and mDCF.